PTLF — Petlife Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Petlife Pharmaceuticals, fiscal year end - August 31st, USD millions except per share, conversion factor applied.

	2013 August 31st	2014 August 31st	2015 August 31st	2016 August 31st	2017 August 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K/A	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	0	0
Cost of Revenue
Gross Profit	—	-0.06	-0.221	0	—
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1.51	1.51	1.93	3.69	22.9
Operating Profit	-1.51	-1.51	-1.93	-3.69	-22.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.62	-1.51	-1.93	-3.69	-23.3
Provision for Income Taxes
Net Income After Taxes	-1.62	-1.51	-1.93	-3.69	-23.3
Minority Interest
Net Income Before Extraordinary Items
Net Income	-1.16	-1.51	-1.93	-3.69	-23.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-1.16	-1.51	-1.93	-3.69	-23.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-115	-0.188	-0.169	-0.404	-0.331
Dividends per Share